Whole-genome amplified DNA from stored dried blood spots is reliable in high resolution melting curve and sequencing analysis.
Winkel BG, Hollegaard MV, Olesen MS, Svendsen JH, Haunsø S, Hougaard DM, Tfelt-Hansen J
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to determine if WGA-DBS stored frozen for 19-28 years have comparable melting curves and sequencing results to fresh blood specimens from patients with atrial fibrillation. DBS obtained at patient birth were stored at -20 degrees C for 19-28 years. DNA was extracted from DBS by Extract-N-amp Blood PCR Kit and amplified with REPLI-g. Fresh blood was obtained from the same patients, and DNA was extracted using the QIAamp mini blood kit. Melting curves were evaluated by high resolution melting curve analysis.
Summary of Findings
Melting curve analysis of 40 amplicons in 10 patients revealed 85 (21%) and 81 (20%) alterations from wild-type using WGA-DBS DNA and fresh genomic DNA, respectively. Although, 64% and 62% of the alterations using WGA-DBS and fresh blood, respectively, were determined to be false positives after sequencing. By sequencing, the same 31 variants were identified using DNA from WGA-DBS and fresh DNA and included 29 heterogeneous and 2 homogeneous changes.
Biospecimens
FluidBloodPreservation Types
Other PreservativeFrozenNone (Fresh)Diagnoses
Cardiovascular DiseaseOther diagnosesPlatforms
DNADNA sequencingDNASNP assayDNAWhole genome amplificationPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition Atrial fibrillationBiospecimen Preservation Type of fixation/preservation Air-driedFrozenNone (fresh)Storage Storage duration 0 days19-28 yearsAnalyte Extraction and Purification Analyte isolation method Extract-N-amp Blood PCR KitQIAamp mini kitSNP assay Specific Nucleic acid amplification NoneREPLI-gSNP assay Specific Targeted nucleic acid KCNA5SCN5ASNP assay Specific Technology platform DNA sequencingHigh resolution melting curve analysis